地西他滨联合半量CAG方案治疗复发难治急性髓系白血病效果观察

Clinical efficacy of decitabine combined with half dose CAG regimen in treatment of patients with relapsed/refractory acute myeloid leukemia

目的 观察地西他滨联合半量CAG方案治疗复发难治急性髓系白血病（AML）的临床效果.方法 收集2015年1月至2017年1月大同市第三人民医院8例接受地西他滨联合半量CAG方案治疗的复发难治AML患者的临床资料,分析其疗效及不良反应.结果 1个疗程地西他滨联合半量CAG方案治疗后,完全缓解3例,部分缓解2例.主要不良反应为骨髓抑制及感染,8例患者均出现Ⅲ～Ⅳ级血液学不良反应,5例出现感染,2例出现Ⅰ级药物性肝损害,无治疗相关死亡发生.结论 地西他滨联合半量CAG方案治疗复发难治AML具有良好疗效,值得进一步研究.

Objective To observe the clinical efficacy of decitabine combined with half dose CAG regimen in patients with relapsed/refractory acute myeloid leukemia （AML）.Methods Clinical data of 8 patients with relapsed/refractory AML who took the therapeutic regimen with decitabine combined with half dose CAG regimen in the Third People＇s Hospital of Datong from January 2015 to January 2017 were collected.The clinical efficacy and adverse effects were observed.Results After one course treatment by decitabine combined with half dose CAG regimen,3 patients achieved complete remission,and 2 patients achieved partial remission.The major adverse reactions were myelosuppression and infection,8 patients appeared grade Ⅲ-Ⅳ myelosuppression,5 patients appeared infection,2 patients appeared grade Ⅰ abnormality of liver and no treatment-related death occurred.Conclusion Decitabine combined with half dose CAG regimen is effective for relapsed/refractory AML,and this regimen is worthy of further study.